Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Other Non-Current Liabilities (2022 - 2024)

Spruce Biosciences (SPRB) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $282000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Other Non-Current Liabilities rose 19.49% to $282000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $282000.0, a 19.49% increase, with the full-year FY2024 number at $282000.0, up 19.49% from a year prior.
  • Other Non-Current Liabilities was $282000.0 for Q4 2024 at Spruce Biosciences, up from $273000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $282000.0 in Q4 2024 to a low of $95000.0 in Q1 2022.
  • A 3-year average of $201500.0 and a median of $211000.0 in 2023 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: skyrocketed 90.53% in 2023, then rose 19.49% in 2024.
  • Spruce Biosciences' Other Non-Current Liabilities stood at $161000.0 in 2022, then surged by 46.58% to $236000.0 in 2023, then increased by 19.49% to $282000.0 in 2024.
  • Per Business Quant, the three most recent readings for SPRB's Other Non-Current Liabilities are $282000.0 (Q4 2024), $273000.0 (Q3 2024), and $262000.0 (Q2 2024).